How Long Does AMD Treatment Last
Wet AMD Treatment Duration
According to ASRS and NCBI Bookshelf (2023-2024), wet AMD requires ongoing, long-term anti-VEGF intravitreal injections. Treatment is considered indefinite because wet AMD is a chronic condition that tends to recur when VEGF suppression stops. The abnormal blood vessels beneath your retina do not disappear; they become dormant under treatment and can reactivate if the medication wears off. Unlike conditions that resolve after a course of treatment, wet AMD requires sustained VEGF suppression to prevent the leaking and bleeding that damages your central vision.
According to the AAO Preferred Practice Pattern (2024), anti-VEGF is recommended as first-line therapy for wet AMD with no defined stopping point. Patients should plan for years of treatment and discuss long-term expectations with their retina specialist early in the process.
Treatment starts with a loading phase of 3 to 4 monthly injections, according to ASRS (2023). After the loading phase, your retina specialist extends the interval between injections based on your OCT imaging. According to published data (Ophthalmologica, 2024), most wet AMD patients require approximately 7 to 8 injections in the first year. Under treat-and-extend protocols, the mean time to reach a 12-week injection interval is approximately 20 months.
Over time, many patients reduce their injection frequency as their disease stabilizes. However, according to the AAO (2024), long-term data show that modest vision gains in year one can erode by year six even with treatment, which underscores the importance of consistent follow-through.
According to ASRS and NCBI Bookshelf (2023-2024), stopping injections without physician guidance risks rapid vision loss from disease reactivation. The fluid and blood from reactivated abnormal vessels can cause new retinal damage within weeks. If you are considering stopping treatment, discuss it with your retina specialist first. Your doctor can monitor you closely during any pause and resume treatment quickly if the disease returns.
Geographic Atrophy Treatment Duration
According to the AAO (2024), injectable treatments for geographic atrophy (pegcetacoplan and avacincaptad pegol) require ongoing monthly or every-other-month injections with no defined end date. GA lesion growth resumes when treatment stops, so the injections continue as long as you and your doctor agree the benefit of slowing progression outweighs the treatment burden. Your retina specialist monitors your lesion size and growth rate at each visit to confirm ongoing benefit.
According to the AAO and manufacturer data (2024), the photobiomodulation light therapy protocol for dry AMD involves 9 sessions over 3 to 5 weeks, repeated every 4 months for a 2-year treatment course. This is currently the only GA treatment with a defined treatment duration, though your doctor may recommend continuing monitoring beyond the two-year course to track your disease.
Injectable complement inhibitors and anti-VEGF drugs treat ongoing disease processes that resume when the drug clears from your eye. Photobiomodulation aims to stimulate cellular repair through repeated light exposure over a fixed period. The difference in treatment mechanism explains why some therapies are indefinite while others have set endpoints. Understanding these distinctions helps you set realistic expectations and plan for the long-term commitment each treatment type requires. Your retina specialist helps you understand what to expect based on which treatment you receive.
Managing Long-Term Treatment
According to published data (MedCentral, 2024), newer anti-VEGF agents such as faricimab allow extended dosing intervals up to every 16 weeks for some patients. High-dose aflibercept can extend even further. Over the course of treatment, many patients reduce from monthly injections to quarterly or less frequent visits. Your retina specialist extends your interval step by step based on OCT findings, always watching for signs that the interval has stretched too far. This gradual extension process may take a year or more as your doctor confirms stability at each new interval before extending further.
According to published literature (PMC, 2025), few clinical guidelines define when it is appropriate to stop anti-VEGF therapy for wet AMD. Decisions to pause or stop are individualized based on imaging findings, visual function, and quality-of-life considerations. Some patients with long-standing stable disease under treatment may attempt a monitored pause, but most continue treatment because the consequences of reactivation are severe.
According to the AAO (2024), patients with dry AMD who are not yet candidates for GA-specific treatment need periodic office visits and home Amsler grid monitoring. The frequency depends on your disease stage: early dry AMD may need annual exams, while intermediate AMD with large drusen may need visits every three to six months. AREDS2 supplements, lifestyle changes, and regular monitoring form the foundation of dry AMD management until active treatment becomes necessary.
Questions About AMD Treatment Duration
Most wet AMD patients need ongoing injections for many years, and many receive them indefinitely. The frequency typically decreases over time as your disease stabilizes and your doctor extends the interval. A small number of patients may eventually pause treatment under close monitoring, but this is not guaranteed. Plan for long-term treatment and discuss your outlook with your retina specialist.
Discuss this with your retina specialist before pausing. Stopping without medical guidance risks disease reactivation and new vision loss. If you need a break due to health issues, travel, or other reasons, your doctor can plan a monitored pause and resume treatment quickly if fluid returns on imaging.
Talk to your retina specialist about medications that support longer dosing intervals, such as faricimab or high-dose aflibercept. Treat-and-extend protocols reduce visit frequency for many patients over time. Some practices offer flexible scheduling, appointment reminders, and coordination of multiple tests on the same day to minimize the time commitment.
Some patients maintain stable disease control for years on the same medication. Others may experience fading response and need a medication switch or interval adjustment. Your retina specialist monitors for changes in treatment effectiveness at every visit and adapts your plan accordingly. Consistent treatment attendance gives you the best chance of maintaining long-term stability.
The total cost depends on your medication, injection frequency, and insurance coverage. Medicare Part B covers anti-VEGF injections for wet AMD, typically leaving a 20 percent coinsurance. Patients with Medigap policies may have most of this covered. Lower-cost options such as bevacizumab and biosimilars help make long-term treatment financially sustainable. Discuss cost concerns with your retina specialist early in your treatment.
Your retina specialist stays current with new FDA approvals, extended-interval formulations, and emerging therapies. As new options become available, your doctor may recommend transitioning to a treatment that offers fewer injections, a different mechanism, or improved outcomes. The AMD treatment landscape continues to evolve, and your plan can evolve with it.
Commit to Your Long-Term Treatment Plan
AMD treatment is a long-term partnership between you and your retina specialist. Consistent attendance, open communication about treatment burden, and willingness to adjust the plan over time give you the best outcomes for preserving your vision through the years ahead.